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Abstract
A series of N,N-dimethylcarbamates containing a N,N-dibenzylamino moiety was synthesized
and tested to evaluate their ability to inhibit Acetylcholinesterase (AChE). The most active
compounds 4 and 8, showed 85 and 69% of inhibition at 50 mM, respectively. Furthermore,
some basic SAR rules were outlined: an alkyl linker of six methylene units is the best spacer
between the carbamoyl and dibenzylamino moieties; electron-withdrawal substituents on
aromatics rings of the dibenzylamino group reduce the inhibitory power. Compound 4
produces a slow onset inhibition of AChE and this is not due to the carbamoylation of the
enzyme, as demonstrated by the time-dependent inhibition assay of AChE with compound 4
and by MALDI-TOF MS analysis of trypsinized AChE inhibited by compound 4. Instead,
compound 4 could act as a slow-binding inhibitor of AChE, probably because of its high
conformational freedom due to the linear alkyl chain.
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Introduction
Acetylcholinesterase (AChE) plays a pivotal role in the termin-
ation of synaptic transmission by rapid hydrolysis of the
neurotransmitter acetylcholine (ACh) into acetate and choline in
the synaptic cleft, after the neurotransmitter release from the
presynaptic nerve terminal1. AChE is present in both the central
and peripheral nervous systems, including at the neuromuscular
junction2–4.
AChE is a serine hydrolase belonging to the esterase family. Its
active site contains two subsites, the ‘‘esterasic’’ and ‘‘anionic’’
subsites. The esterasic site, where ACh is hydrolyzed, contains the
catalytic triad of three amino acids: Ser203 (the amino acids
numbering, unless otherwise specified, refer to the human AChE),
His447 and Glu3345. The contiguous anionic subsite, called
catalytic ‘‘anionic’’ site (CAS), recognizes the quaternary group
of ACh via -cation interactions with aromatic residues; here,
among the aromatic amino acids, Trp86 is critical for this role6. A
second anionic-binding site for ACh, known as ‘‘peripheral’’
anionic site (PAS), lies on the surface of AChE approximately
20 A˚ distant from the active site. The PAS consists of five residues
(Tyr72, Asp74, Tyr124, Trp286 and Tyr337) involved in the
allosteric modulation of catalysis at the active site and is the target
of various anti-cholinesterase drugs. It is also implicated in a
number of non-classical functions, in particular, amyloid depos-
ition, cell adhesion and neurite outgrowth7. A gorge, surrounded
by aromatic amino acidic residues and with a length of about
20 A˚, connects the PAS to the active site8.
The inhibition of AChE, by compounds that interact with the
CAS and or with the PAS, has, as a consequence, a prolongation
of the persistency of acetylcholine in the synaptic cleft and hence
an increase in cholinergic tone. For this reason, AChE is still a
therapeutic target for the symptomatic treatment of Alzheimer’s
disease (AD) because it is associated with a cholinergic deficit9.
AChE inhibitors (AChEIs) have also been suggested for other
possible therapeutic applications, i.e. Wernicke–Korsakoff syn-
drome10 and posttraumatic cognitive impairments11.
Furthermore, besides of its cholinergic role, in the AD the
AChE plays a non-cholinergic role accelerating beta-amyloid
plaques assembly12. Thus, the AChEIs can now be seen in new
perspectives, being able to restore the compromised cholinergic
tone and at the same time interfering with the AChE-induced
amyloid deposition.
In Chart 1 the main AChEIs approved for the treatment of AD
are represented13. Tacrine was described as reversible inhibitor,
interacting with Trp86 at CAS; its use has actually been
abandoned due to the high incidence of the side effects.
Donepezil (Aricept) is a reversible inhibitor that binds the
PAS, it is indicated for the use in the palliative treatment of mild
to moderate AD. Galantamine (Razadyn, Nivalin) is a
reversible inhibitor that interacts with anionic subsite and with
the aromatic gorge; it is indicated for the treatment of mild to
moderate AD and other memory impairments. Rivastigmine
(Exelon) is a slow-acting inhibitor that covalently binds to
Ser203 blocking esterasic activity; it has been approved for the
treatment of mild to moderate AD.
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Agents as Rivastigmine, that contain a carbamyl group, are
typical pseudo-irreversible AChEIs14,15 that give carbamylation
of active site serine residue and form a carbamoyl–enzyme
intermediate that will be slowly hydrolyzed in order to give back
the native enzyme.
Here, we report the synthesis, the characterization and the
AChE inhibition properties of new series of carbamate derivatives
(Chart 2). For this series of compounds, we have chosen a small
dimension N,N-dimethylcarbamic function, in order to allow its
entrance through the cramped catalytic gorge. With the aim of
optimize the interaction of synthesized compounds with aromatic
amino acids characterizing the PAS and the access gorge, we have
added an N,N-dibenzylamino moiety. These two fragments were
linked by means of a flexible alkyl chain with variable length,
comprised between 3 and 6 methylenic units. The synthesized
compounds should inhibit AChE through combined interactions:
the carbamic function could interact with the amino acid residues
of the catalytic site (esterasic and anion subsite); in addition, the
N,N-dibenzylamino group should also interact with the aromatic
amino acid residues of the PAS. Because of the difficulty to
predict the conformational behavior of linear alkyl chains, we
chose to use different length chains to connect the aromatic and
the carbamic moieties. Furthermore, we also evaluate the effects
of electron withdrawal or electron donor substituents on the
aromatic groups.
The synthesized compounds were evaluated for the AChEIs
activity and the most active compound was studied, by UV and
MALDI mass spectrometry, in order to demonstrate if it is really
able to produce the carbamylation of AChE.
Materials and methods
Chemical synthesis
All reagents, solvents and deuterated were purchased from Sigma-
Aldrich (Milano, Italy). Acetonitrile was freshly purified by
distillation over calcium hydride. 1H and 13C NMR spectra were
recorded on AVANCE200 Bruker spectrometer operating at 200
and 50 MHz, respectively; chemical shifts () are given in ppm,
relatively to TMS as internal reference, coupling constant are
given in Hertz. The following abbreviations were used, s¼ sing-
let, d¼ doublet, t¼ triplet, q¼ quartet, m¼multiplet. Mass
spectra were acquired on a GC-MS mass spectrometer Hewlett-
Packard 5890 series II equipped with a mass selective detector
Hewlett-Packard 5971 series II.
Synthesis of carbamates 1–14
The synthesis of carbamates 1–14 was carried out following two
different strategies (due to the low yields): N,N-dibenzylation of
the amino alcohol followed by dimethylcarbamoylation (Route A)
or dimethylcarbamoylation of the amino alcohol and subsequent
N,N-dibenzylation (Route B). The higher yields in carbamates
were obtained following Procedure B.
Route A. To a solution of amino alcohol (1.0 mmol) in 5.0 mL
MeCN, benzyl bromide (3.0 mmol) was added dropwise and the
mixture was kept under stirring at room temperature for 24 h.
Then, Et3N (6.0 mmol) was added dropwise at room temperature
and the mixture was kept under stirring at room temperature for
48 h. The solvent was evaporated under reduced pressure and the
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Chart 2. Synthesized carbamates 1–14.
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1 : R = H; n = 1 8   : R = CH3; n = 4
2 : R = H; n = 2 9   : R = F; n = 1
3 : R = H; n = 3 10 : R = F; n = 2
4 : R = H; n = 4 11 : R = F; n = 4
5 : R = CH3; n = 1 12 : R = CF3; n = 1
6 : R = CH3; n = 2 13 : R = CF3; n = 2
7 : R = CH3; n = 3 14 : R = CF3; n = 4
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residue was extracted using ethyl acetate. After evaporation of the
solvent under reduced pressure, usually pure dibenzylamino
alcohol was obtained (48–79% yields). Dibenzylamino alcohol
thus obtained (0.7 mmol), N,N-dimethylaminocarbamoyl chloride
(1.0 mmol) and freshly distilled pyridine (1.0 mmol) in CH2Cl2
(2.0 mL) were kept under stirring at room temperature for three
days; then the solvent was evaporated under reduced pressure and
the product was purified by flash column chromatography (n-
hexane: ethyl acetate from 9:3 to 7:3 as eluent). Yields: 5–15%.
Route B. To a solution of amino alcohol (1.0 mmol) in 5.0 mL
MeCN, HCl gas was bubbled for 3–4 min; then N2 gas was
bubbled into the mixture to eliminate HCl excess. N,N-
dimethylaminocarbamoyl chloride (1.0 mmol) was added to the
mixture and the solution was refluxed for 12 h. The product was
used in the following reaction without further purification. Benzyl
bromide (3.0 mmol) was added to the solution and the mixture
was kept at room temperature under stirring for 3 h; the mixture
refluxed for 12 h, then triethylamine (3.0 mmol) was added and
the mixture refluxed for 2 days. The solvent was evaporated under
reduced pressure and the product was purified by flash column
chromatography (n-hexane: ethyl acetate from 9:3 to 7:3 as
eluent). Yields: 15–40%.
Characterization data
The characterization data for the synthesized compounds are
given below.
3-(Dibenzylamino)propan-1-ol (15a): 1H NMR (200 MHz,
CDCl3)  1.73–1.83 (m, 2H), 2.67 (t, J¼ 5.9 Hz, 2H), 3.61 (s,
4H), 3.64 (t, J¼ 5.4 Hz, 2H), 7.25–7.35 (m, 10H); 13C NMR
(50 MHz, CDCl3)  27.9, 52.9, 58.4, 63.5, 126.8, 128.4, 129.0,
137.8; EIMS, m/z: M.+ absent, 210 (17%), 91 (100%), 65 (24%),
44 (36%).
4-(Dibenzylamino)butan-1-ol (15b) 1H NMR (200 MHz,
CDCl3)  1.55–1.64 (m, 2H), 1.71–1.77 (m, 2H), 2.57 (t,
J¼ 6.3 Hz, 2H), 3.58 (t, J¼ 5.7 Hz, 2H), 3.70 (s, 4H), 7.27–7.42
(m, 10H); 13C NMR (50 MHz, CDCl3)  23.9, 30.9, 53.4, 58.1,
62.1, 127.5, 128.4, 129.5, 137.5; EIMS, m/z: M.+ absent, 210
(13%), 148 (18%), 91 (100%), 65 (20%).
5-(Dibenzylamino)pentan-1-ol (15c): 1H NMR (200 MHz,
CDCl3)  1.25–1.61 (m, 6H), 2.47 (t, J¼ 7.0 Hz, 2H), 3.56–7.62
(m, 6H), 7.25–7.41 (m, 10H); 13C NMR (50 MHz, CDCl3)  23.3,
26.5, 32.4, 53.0, 58.2, 62.8, 127.0, 128.2, 129.0, 139.0; EIMS,
m/z: 283 (M.+, 1%), 210 (32%), 91 (100%), 65 (11%).
6-(Dibenzylamino)hexan-1-ol (15d): 1H NMR (200 MHz,
CDCl3)  1.25–1.30 (m, 2H), 1.44–1.56 (m, 2H), 2.45 (t,
J¼ 7.2 Hz, 2H), 3.56–7.63 (m, 6H), 7.25–7.42 (m, 10H); 13C
NMR (50 MHz, CDCl3)  25.4, 26.8, 32.7, 52.9, 58.1, 62.9, 127.0,
128.2, 129.0, 139.0; EIMS, m/z: M.+ absent, 210 (30%), 91
(100%), 73 (25%).
3-(Bis(4-methylbenzyl)amino)propan-1-ol (15e): 1H NMR
(200 MHz, CDCl3)  1.86–1.91 (m, 2H), 2.37 (s, 6H), 2.77–2.80
(m, 2H), 3.69–3.74 (m, 6H), 7.12–7.29 (m, 8H); 13C NMR
(50 MHz, CDCl3) d 21.4, 27.9, 52.7, 58.3, 63.0, 126.4, 128.3,
128.4, 130.1, 137.1, 138.0; EIMS, m/z: M.+ absent, 238 (19%),
105 (100%), 77 (12%).
4-(Bis(4-methylbenzyl)amino)butan-1-ol (15f): 1H NMR
(200 MHz, CDCl3)  1.58–1.74 (m, 4H), 2.34 (s, 6H), 2.52 (t,
J¼ 6.1 Hz, 2H), 3.58 (t, J¼ 5.4 Hz, 2H), 3.61 (s, 4H), 7.07–7.28
(m, 8H); 13C NMR (50 MHz, CDCl3)  21.4, 24.2, 31.1, 53.4,
58.1, 62.5, 126.5, 128.1, 128.3, 130.3, 137.2, 137.9; EIMS, m/z:
297 (M.+, 1%), 238 (19%), 105 (100%), 84 (23%).
6-(Bis(4-methylbenzyl)amino)hexan-1-ol (15 h): 1H NMR
(200 MHz, CDCl3)  1.28–1.33 (m, 4H), 1.43–1.64 (m, 4H),
2.36 (s, 6H), 2.49–2.56 (m, 2H), 3.60 (t, J¼ 6.4 Hz, 2H), 3.69 (s,
4H), 7.09–7.12 (m, 4H), 7.23–7.27 (m, 4H); 13C NMR (50 MHz,
CDCl3)  21.5, 25.6, 26.5, 27.0, 32.7, 53.1, 58.1, 62.5, 126.2,
127.8, 128.1, 129.9, 137.7, 138.6; EIMS, m/z: M.+ absent, 238
(1%), 105 (100%), 79 (21%).
3-(Bis(4-fluorobenzyl)amino)propan-1-ol (15i): 1H NMR
(200 MHz, CDCl3)  1.77–1.89 (m, 2H), 2.73 (t, J¼ 6.0 Hz,
2H), 3.65 (m, 6H), 7.09–7.00 (m, 4H), 7.38–7.31 (m, 4H); 13C
NMR (50 MHz, CDCl3) d 28.1, 52.5, 57.5, 63.1, 115.2
(d, J¼ 21.3 Hz), 130.7 (d, J¼ 8.0 Hz), 133.6 (d, J¼ 3.2 Hz),
162.0 (d, J¼ 245.3 Hz); EIMS, m/z: M.+ absent, 231 (7%), 136
(25%), 123 (34%), 109 (100%), 95 (30%).
4-(Bis(4-fluorobenzyl)amino)butan-1-ol (15 l): 1H NMR
(200 MHz, CDCl3)  1.60–1.63 (m, 2H), 2.64 (t, J¼ 5.4 Hz,
2H), 3.55 (t, J¼ 5.0 Hz, 2H), 3.71 (s, 4H), 6.93–7.01 (m, 4H),
7.21–7.28 (m, 4H); 13C NMR (50 MHz, CDCl3)  28.3, 32.2, 49.2,
53.1, 62.4, 115.2 (d, J¼ 21.2 Hz), 129.8 (d, J¼ 8.0 Hz), 134.9 (d,
J¼ 3.2 Hz), 162.0 (d, J¼ 245.0 Hz); EIMS, m/z: M.+ absent, 246
(11%), 109 (100%), 83 (18%).
6-(Bis(4-fluorobenzyl)amino)hexan-1-ol (15m):1H NMR
(200 MHz, CDCl3)  1.25–1.32 (m, 2H), 1.40–1.58 (m, 2H),
2.37–2.49 (m, 2H), 3.57–3.64 (m, 6H), 6.99–7.07 (m, 4H), 7.30–
7.37 (m, 4H); 13C NMR (50 MHz, CDCl3)  25.5, 26.7, 27.0, 32.6,
53.0, 57.3, 62.6, 114.9 (d, J¼ 21.2 Hz), 130.3 (d, J¼ 7.8 Hz),
134.9 (d, J¼ 2.9 Hz), 161.9 (d, J¼ 244.4 Hz); EIMS, m/z:
M.+ absent, 246 (1%), 109 (100%), 83 (21%).
3-(Bis(4-(trifluoromethyl)benzyl)amino)propan-1-ol (15n): 1H
NMR (200 MHz, CDCl3)  1.75–1.87 (m, 2H), 2.65 (t, J¼ 6.1 Hz,
2H), 3.64 (s, 4H), 3.68 (t, J¼ 5.6 Hz, 2H), 7.45 (d, J¼ 8.2 Hz,
4H), 7.60 (d, J¼ 8.2 Hz, 4H); 13C NMR (50 MHz, CDCl3)  28.4,
52.9, 58.2, 63.1, 124.1 (q, J¼ 271.9 Hz), 125.5 (q, J¼ 3.8 Hz),
129.2, 129.7 (q, J¼ 32.4 Hz), 142.3; EIMS, m/z: M.+ absent, 159
(100%), 140 (8%), 109 (41%), 69 (5%).
4-(Bis(4-(trifluoromethyl)benzyl)amino)butan-1-ol (15o): 1H
NMR (200 MHz, CDCl3)  1.55–1.71 (m, 4H), 2.50 (t, J¼ 6.2 Hz,
2H), 3.61 (t, J¼ 5.7 Hz, 2H), 3.65 (s, 4H), 7.48 (d, J¼ 8.2 Hz,
4H), 7.60 (d, J¼ 8.2 Hz, 4H); 13C NMR (50 MHz, CDCl3) d 23.9,
30.7, 53.8, 58.0, 62.4, 124.2 (q, J¼ 271.8 Hz), 125.2 (q,
J¼ 3.8 Hz), 129.1, 129.3 (q, J¼ 32.2 Hz), 143.1; EIMS, m/z:
M.+ absent, 346 (21%), 159 (100%), 140 (9%), 109 (31%).
6-(Bis(4-(trifluoromethyl)benzyl)amino)hexan-1-ol (15p): 1H
NMR (200 MHz, CDCl3)  1.27–1.33 (m, 4H), 1.50–1.57 (m,
4H), 2.43 (t, J¼ 6.9 Hz, 2H), 3.64–3.58 (m, 6H), 7.47 (d,
J¼ 8.0 Hz, 4H), 7.58 (d, J¼ 8.0 Hz, 4H); 13C NMR (50 MHz,
CDCl3)  25.5, 26.9, 32.6, 53.7, 58.0, 62.6, 124.3 (q,
J¼ 273.3 Hz), 125.4 (q, J¼ 3.8 Hz), 128.8, 129.2 (q,
J¼ 32.2 Hz), 144.0; EIMS, m/z: M.+ absent, 346 (12%), 159
(100%), 140 (7%), 109 (19%).
3-(Dibenzylamino)propyl dimethylcarbamate1: 1H NMR
(200 MHz, CDCl3)  1.81–1.88 (m, 2H), 2.50–2.62 (m, 2H),
2.62 (bs, 3H), 2.87 (bs, 3H), 3.58 (s, 4H), 4.11 (t, J¼ 6.3 Hz, 2H),
7.26–7.40 (m, 10H); 13C NMR (50 MHz, CDCl3)  26.6, 35.6,
36.3, 49.5, 58.3, 63.1, 126.7, 128.2, 128.7, 139.7, 156.5; EIMS,
m/z: M.+ absent, 145 (100%), 117 (35%), 102 (15%), 91 (62%),
72 (41%).
4-(Dibenzylamino)butyl dimethylcarbamate2: 1H NMR
(200 MHz, CDCl3)  1.60–1.63 (m, 4H), 2.43–2.47 (m, 2H),
2.88 (s, 6H), 3.57 (bs, 4H), 4.01 (t, J¼ 6.0 Hz, 2H), 7.23–7.40 (m,
10H); 13C NMR (50 MHz, CDCl3)  23.5, 26.9, 35.9, 36.3, 53.0,
58.3, 65.2, 126.8, 128.2, 128.7, 139.8, 156.7; EIMS, m/z:
M.+ absent, 158 (68%), 118 (29%), 91 (100%), 72 (52%).
4-(Dibenzylamino)pentyl dimethylcarbamate3: 1H NMR
(200 MHz, CDCl3)  1.34–1.43 (m, 2H), 1.49–1.59 (m, 4H),
2.45 (t, J¼ 6.9 Hz, 2H), 2.90 (s, 6H), 3.57 (bs, 4H), 4.04 (t,
J¼ 6.4 Hz, 2H), 7.24–7.41 (m, 10H); 13C NMR (50 MHz, CDCl3)
d 23.6, 26.6, 28.9, 35.9, 36.2, 53.1, 58.3, 65.3, 126.8, 128.1,
128.8, 139.8, 156.8; EIMS, m/z: M.+ absent, 263 (13%), 210
(51%), 91 (100%), 72 (17%).
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6-(Dibenzylamino)hexyl dimethylcarbamate4: 1H NMR
(200 MHz, CDCl3)  1.27 (bm, 4H), 1.56 (bm, 4H), 2.44 (bm,
2H), 2.89 (s, 6H), 3.58 (bs, 4H), 4.01 (t, J¼ 6.6 Hz, 2H), 7.27–
7.37 (m, 10H); 13C NMR (50 MHz, CDCl3)  25.7, 26.8, 29.0,
35.9, 36.2, 53.9, 58.0, 65.3, 127.1, 128.3, 129.1, 139.7, 156.8;
EIMS, m/z: M.+ absent, 210 (11%), 91 (100%), 72 (30%),
42 (26%).
3-(Bis(4-methylbenzyl)amino)propyl dimethylcarbamate5: 1H
NMR (200 MHz, CDCl3)  1.58 (bs, 8H), 2.35 (m, 2H), 2.88
(bs, 6H), 3.52 (s, 4H), 4.02 (t, J¼ 6.3 Hz, 2H), 7.06–7.43 (m, 8H);
13C NMR (50 MHz, CDCl3)  21.4, 26.6, 35.7, 36.3, 49.5, 58.3,
63.3, 125.9, 127.6, 128.1, 129.6, 137.7, 139.5, 156.6; EIMS, m/z:
M.+ absent, 105 (100%), 72 (59%), 42 (53%).
4-(Bis(4-methylbenzyl)amino)butyl dimethylcarbamate6: 1H
NMR (200 MHz, CDCl3)  1.61–1.63 (m, 4H), 2.36 (s, 6H),
2.46 (m, 2H), 2.88 (s, 6H), 3.55 (bs, 4H), 4.02 (t, J¼ 6.1 Hz, 2H),
7.08–7.27 (m, 8H); 13C NMR (50 MHz, CDCl3)  21.4, 26.9, 29.7,
35.8, 36.1, 52.8, 58.1, 65.1, 125.9, 127.6, 128.1, 129.7, 137.8,
139.6, 156.7; EIMS, m/z: M.+ absent, 263 (3%), 238 (8%), 105
(100%), 91 (9%).
6-(Bis(4-methylbenzyl)amino)pentyl dimethylcarbamate7:
1H NMR (200 MHz, CDCl3)  1.29–1.41 (m, 2H), 1.55–1.641
(m, 4H), 2.37 (s, 6H), 2.41–2.44 (m, 2H), 2.91 (s, 6H), 3.55 (s,
4H), 4.05 (t, J¼ 6.4 Hz, 2H), 7.06–7.09 (m, 2H), 7.19–7.23 (m,
6H); 13C NMR (50 MHz, CDCl3)  21.4, 23.6, 26.6, 28.9, 35.9,
36.2, 53.1, 58.3, 65.4, 125.9, 127.5, 128.0, 129.6, 137.6, 139.7,
156.8; EIMS, m/z: 382 (M.+, 1%), 277 (16%), 238 (82%),
105 (100%).
6-(Bis(4-methylbenzyl)amino)hexyl dimethylcarbamate8: 1H
NMR (200 MHz, CDCl3)  1.28–1.33 (m, 4H), 1.51–1.64 (m,
4H), 2.36 (s, 6H), 2.43 (t, J¼ 6.8 Hz, 2H), 2.91 (s, 6H), 3.54 (s,
4H), 4.04 (t, J¼ 6.6 Hz, 2H), 7.04–7.07 (m, 4H), 7.19–7.26 (m,
4H); 13C NMR (50 MHz, CDCl3)  21.4, 25.8, 26.9, 29.1, 35.8,
36.3, 53.2, 58.2, 65.4, 125.9, 127.5, 128.0, 129.6, 137.6, 139.7,
156.9; EIMS, m/z: M.+ absent, 238 (23%), 133 (18%), 105 (100%).
3-(Bis(4-fluorobenzyl)amino)propyl dimethylcarbamate9: 1H
NMR (200 MHz, CDCl3)  1.77–1.84 (m, 2H), 2.45–2.51 (m, 2H),
2.63 (bs, 3H), 2.87 (bs, 3H), 3.50 (s, 4H), 4.08 (t, J¼ 6.2 Hz, 2H),
6.94–7.03 (m, 4H), 7.26–7.33 (m, 4H); 13C NMR (50 MHz,
CDCl3)  26.5, 35.5, 36.2, 49.2, 57.5, 62.9, 115.0 (d, J¼ 21.3 Hz),
130.1 (d, J¼ 7.8 Hz), 135.1, 156.5, 161.9 (d, J¼ 244.5 Hz);
EIMS, m/z: M.+ absent, 109 (100%), 89 (4%), 72 (24%), 42 (17%).
4-(Bis(4-fluorobenzyl)amino)butyl dimethylcarbamate10: 1H
NMR (200 MHz, CDCl3)  1.56–1.61 (m, 4H), 2.40–2.42 (m,
2H), 2.88 (bs, 6H), 3.49 (s, 4H), 4.00 (t, J¼ 6.2 Hz, 2H), 6.96–
7.04 (m, 4H), 7.27–7.33 (m, 4H); 13C NMR (50 MHz, CDCl3) 
23.5, 26.9, 35.9, 36.2, 52.9, 57.5, 65.1, 114.9 (d, J¼ 21.4 Hz),
130.0 (d, J¼ 4.7 Hz), 135.2 (d, J¼ 1.6 Hz), 156.8, 162.0 (d,
J¼ 260.9 Hz); EIMS, m/z: M.+ absent, 246 (3%), 109 (100%), 72
(30%), 42 (19%).
6-(Bis(4-fluorobenzyl)amino)hexyl dimethylcarbamate11: 1H
NMR (200 MHz, CDCl3)  1.28–1.31 (m, 4H), 1.50–1.62 (m, 4H),
2.36 (s, 6H), 2.38 (t, J¼ 6.6 Hz, 2H), 2.90 (s, 6H), 3.49 (s, 4H),
4.02 (t, J¼ 6.6 Hz, 2H), 6.95–7.04 (m, 4H), 7.27–7.33 (m, 4H);
13C NMR (50 MHz, CDCl3)  25.7, 26.9, 29.0, 35.9, 36.3, 53.2,
57.4, 65.3, 114.9 (d, J¼ 21.3 Hz), 130.0 (d, J¼ 7.5 Hz), 135.4 (d,
J¼ 2.0 Hz), 156.8, 161.8 (d, J¼ 242.4 Hz); EIMS, m/z:
M.+ absent, 246 (4%), 109 (100%), 72 (21%), 42 (10%).
3-(Bis(4-(trifluoromethyl)benzyl)amino)propyl dimethylcarba-
mate12: 1H NMR (200 MHz, CDCl3)  1.71–1.88 (m, 2H), 2.48–
2.55 (m, 2H), 2.55 (bs, 3H), 2.86 (bs, 3H), 3.61 (s, 4H), 4.12
(t, J¼ 6.1 Hz, 2H), 7.47 (d, J¼ 8.2 Hz, 4H), 7.57 (d, J¼ 8.2 Hz,
4H); 13C NMR (50 MHz, CDCl3)  26.5, 35.4, 36.2, 49.7, 58.1,
62.7, 124.1 (q, J¼ 271.8 Hz), 125.2 (q, J¼ 3.7 Hz), 128.8 (q,
J¼ 52.2 Hz), 128.9, 143.6, 156.4; EIMS, m/z: M.+ absent, 346
(10%), 303 (35%), 214 (38%), 159 (100%), 109 (17%), 72 (19%).
4-(Bis(4-(trifluoromethyl)benzyl)amino)butyl dimethylcarba-
mate13: 1H NMR (200 MHz, CDCl3)  1.59–1.63 (m, 4H), 2.47
(bs, 2H), 2.87 (bs, 6H), 3.61 (s, 4H), 4.03 (t, J¼ 6.2 Hz, 2H), 7.47
(d, J¼ 8.2 Hz, 4H), 7.57 (d, J¼ 8.2 Hz, 4H); 13C NMR (50 MHz,
CDCl3)  23.6, 26.9, 35.8, 36.3, 53.4, 58.0, 65.0, 124.1 (q,
J¼ 272.7 Hz), 125.2, 128.8, 129.0 (q, J¼ 52.2 Hz), 143.6, 156.6;
EIMS, m/z: M.+ absent, 332 (100%), 186 (66%), 159 (76%),
69 (17%).
6-(Bis(4-(trifluoromethyl)benzyl)amino)hexyl dimethylcarba-
mate14: 1H NMR (200 MHz, CDCl3)  1.27–1.33 (m, 4H), 1.53–
1.58 (m, 4H), 2.42 (t, J¼ 7.0 Hz, 2H), 2.89 (s, 6H), 3.60 (s, 4H),
4.03 (t, J¼ 6.7 Hz, 2H), 7.47 (d, J¼ 8.2 Hz, 4H), 7.57 (d,
J¼ 8.2 Hz, 4H); 13C NMR (50 MHz, CDCl3)  25.8, 26.9, 26.9,
29.0, 35.8, 36.2, 53.7, 58.0, 65.2, 124.2 (q, J¼ 271.7 Hz), 125.1
(q, J¼ 3.8 Hz),128.8, 129.2 (q, J¼ 32.2 Hz), 143.9, 156.8; EIMS,
m/z: M.+ absent, 346 (94%), 159 (100%), 90 (4%).
Enzymatic tests
The spectrophotometric method of Ellman16 with minor modifi-
cations17,18 was used to evaluate the inhibition of AChE. Electric
eel AChE (AChE, EC 3.1.1.7), acetylthiocholine iodide, 5,50-
dithio-bis-(2-nitrobenzoic acid) (DTNB), donepezil, used as
reference standard, and carbaryl (1-naphthyl methylcarbamate)
were purchased from Sigma-Aldrich (Milan, Italy). The sequen-
cing grade modified trypsin was purchased from Promega (Milan,
Italy). The assay was carried out by double beam UV-Vis lambda
40 Perkin Elmer spectrophotometer, using optical polystyrene
cuvettes (10 10 45 mm, 340–800 nm optical transparency).
Each compound was dissolved in DMSO in the opportune
quantity in order to obtain a final cuvette DMSO content50.05%,
that does not affect the enzyme activity.
Percent inhibition of AChE
Aliquots of 3.0 mL of 0.1 M (pH 7.4) phosphate buffer containing
DTNB (0.25 mM) and AChE (0.083 U mL1) were placed in a
polystyrene cuvette of 1.0 cm path length; 1mL of a solution
150 mM in DMSO of the tested compound was added. To start the
reaction 30 mL of an aqueous solution in phosphate buffer
(pH¼ 7.4) of acetylthiocoline (10 mM) were added. The increase
in the absorbance, due to the production of the yellow 5-nitro-2-
tio benzoic anion, was recorded at 412 nm and 25 C between 0.5
and 1.5 min. As a control, an identical solution of the enzyme
without the inhibitor was processed following the same protocol
to determine the 100% of enzyme activity.
Each experiment was repeated at least in triplicate. The
potency of each compound to inhibit AChE activity was expressed
as percent inhibition calculated using the following equation:
Inhibition %ð Þ ¼ Ac  Ai
Ac
 100
where Ai and Ac represent the change in the absorbance in the
presence of inhibitor and without inhibitor, respectively.
Time-dependent inhibition assay for compound 4
Aliquots of 3.0 mL of 0.1 M (pH 7.4) phosphate buffer containing
DTNB (0.25 mM) and AChE (0.083 U mL1) were mixed in a
polystyrene cuvette of 1 cm path length with 1mL of a solution
15 mM in DMSO of the compound 4, obtaining a 5mM final
concentration. Immediately after, acetylthiocoline (30 mL, 10 mM)
was added. Then, the change in the absorbance was recorded. In
order to obtain a reference enzymatic activity (negative control), a
solution containing the enzyme without the inhibitor was
processed in the same way. After 40 min of incubation, the
inhibition percentage was measured again, both for AChE
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incubated with 4 and for the negative control, using the protocol
above described. As a positive control of the carbamylation
reaction, a 1mM carbaryl solution was used.
At the same time a solution of AChE (0.083 U mL1) in
25.0 mL of 0.1 M phosphate buffer pH 7.4 was prepared. From
this stock solution of AChE, three aliquots of 2.0 mL each were
taken: solution A, containing compound 4 (40mM); solution B,
with carbaryl (4 mM); solution C, that was left as it was for having
a negative control. Each solution was incubated at 37 C for 2 h.
The buffer solution with residual inhibitor, if presents, was
removed from the incubation mixture by centrifugation and
ultrafiltration, using Vivaspin 2 device with membrane 3000
MWCO PES (Sartorius Stedim Biotech GmbH, Goettingen,
Germany); the residual content was washed with 2 mL of
phosphate buffer and then taken up with 3.0 mL of phosphate
buffer containing DTNB (0.25 mM) to measure the inhibition
percentage as described above.
Mass spectrometry analysis
Preparation of AChE
Fifty micrograms of AChE in 500 mL of 50 mM sodium phosphate
buffer at pH 7.4 were incubated with compound 4 (200 mM) or
carbaryl (200 mM). The control sample of AChE was incubated
only with buffer. After incubation at 37 C for 2 h, residual
inhibitor was removed from the incubation mixture by centrifu-
gation and ultrafiltration, using Vivaspin 2 device. The buffer was
exchanged to 50 mM ammonium bicarbonate buffer. Each sample
was concentrated and then taken up with MeCN to denature the
enzyme. The samples were subjected to proteolytic digestion by
overnight incubation with sequencing grade modified trypsin,
0.02 mg mL1 in 50 mM acetic acid (1:50 protein ratio of trypsin/
AChE), at room temperature. The digested samples were
concentrated under reduce pressure and then dissolved in
200mL of H2O-MeCN-TFA (100:20:0.02) for the mass spectrom-
etry analysis.
MALDI-TOF-MS analysis
Matrix-assisted laser desorption/ionization time-of-flight mass
spectrometry (MALDI-TOF MS) was performed on a PE
Biosystems Voyager DE mass spectrometer (Houston, TX).
Mass spectra were acquired in positive-ion linear mode under
delayed extraction conditions, using an acceleration voltage of
23 kV and laser intensity of 3500 V with a 337 nm pulsed nitrogen
laser. External calibration was performed using human insulin
(5807.57 Da). Trypsinized AChE were mixed with a matrix of
5 mg mL1 a-cyano-4-hydroxycinnamic acid (CHCA) in 50%
(v/v) acetonitrile/water 0.3% (v/v) TFA, pH 2.2. Aliquot of 1mL
peptidematrix mixture was spotted on a polished MALDI-TOF
MS target plate and dried by evaporation at ambient temperature.
Analyte-matrix co-crystals appeared homogeneous in nature. The
mass spectra were the average of 256 laser shots collected from
multiple locations on the target spot and monitored by a digital
oscilloscope during acquisition.
Molecular docking study
The crystal structure of Torpedo californica AChE (TcAChE)
complexed with donepezil (code: 1EVE, resolution of 2.50 A˚) was
downloaded from PDB (http://www.rcsb.org). Prior to performing
molecular docking, the protein PDB file was prepared using the
Dock Prep tool available in the free software package UCSF
Chimera 1.10.119. This involved the addition of hydrogen atoms,
removal of water molecules and assigning partial charges (using
the AMBER99 force field). Docking calculations were carried out
using SwissDock, an online server that docks ligand to protein
using EADock DSS software20,21. Docking runs were performed
using the ‘‘Accurate’’ parameters option, which is the most
exhaustive in terms of the number of binding modes sampled.
Output clusters were obtained after each docking run and were
ranked according to the FullFitness (FF) scoring function
specified by the SwissDock algorithm (cluster 0 being the cluster
with the best FF score). A greater negative FF score indicates a
more favorable binding mode with a better fit. Within each
cluster, the individual binding poses were further arranged and
ranked based on their FF score. Results of the SwissDock were
visualized by UCSF Chimera package. Re-docking experiment
with natural ligand (Donepezil) was carried out in order to
evaluate the ability of the software to correctly recognize the
AChE-binding site.
Results and discussion
Chemistry
The synthesis of carbamates 1–14 was firstly achieved following a
two steps procedure (Route A, Scheme 1): N,N-dibenzylation of
an a,!-amino alcohol followed by the N,N-dimethylcarbamoyla-
tion at the oxygen atom. Unfortunately, the yields of the second
step were very low (5–15%). Consequently, the synthesis of
carbamates 1–14 was achieved (in some cases in higher yields)
following a different pathway (Route B, Scheme 1), in which an
a,!-amino alcohol was transformed into the corresponding
hydrochloride by reaction with gaseous HCl, and then carbamoy-
lated at the oxygen atom by reaction with N,N-dimethylcarbamoyl
chloride. The following reaction with benzyl bromide led to the
desired carbamates (15–40% yields). The spectroscopic data are
in good agreement with the proposed structures.
Enzymatic assays
All synthesized compounds were tested to evaluate their ability
to inhibit AChE. The results are reported in Table 1. The most
potent inhibitor4 presents a percent inhibition equal to 85%
at 50mM.
The reported data clearly indicate that two main features
influence the enzyme inhibition: (i) the nature of the R
substituent at the aromatic ring, which plays a key role in the
inhibitory potency; (ii) the length of the alkyl spacer, which
also significantly affects the activity. As shown by the data in
Table 1, the most active compounds are 4 (R¼H; n¼ 4) and 8
(R¼CH3; n¼ 4) with a percent inhibition, at 50 mM, of 85 and
69%, respectively. These compounds are characterized by
unsubstituted aromatic rings4 or substituted with a para-
methyl group8; their electron density is suitable to allow
interactions with the aromatic residues in the active enzymatic
site. When the aromatic ring is substituted by electron
withdrawing groups11,14 a substantial decrease in the activity
is observed (inhibition of 12% and 31%, respectively).
Moreover, 4 and 8 have an alkyl linker separating the
dibenzylamino and the carbamic moieties with six methylene
units. Therefore, this alkyl chain probably represents the best
spacer in terms of length and flexibility.
For compound 4, the inhibition assay on AChE shows a time-
dependent activity: at 5mM concentration of compound 4, the
percentage of inhibition increases from 50%, without incubation,
to 95%, with 40 min of incubation. This strong dependence of
inhibitory potency on incubation time suggests that compound 4
could act as pseudo-irreversible inhibitor, forming a carbamoyl-
AChE complex by covalent interaction with serine in the catalytic
site. Furthermore, the removal of the carbamic function reduced
the inhibitory potency from 85% to 32% in the same experimental
conditions (4 versus 15d).
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To verify the role of the carbamic function on the activity of
the compound 4, we have carried out experiments to evaluate the
reversibility of the enzymatic inhibition.
In particular, we prepared a stock solution of AChE in
phosphate buffer, from which three aliquots were taken to obtain
the solution A (added with compound 4), the solution B (added
with carbaryl, a known carbamylating agent) and the solution C
(without inhibitor). Each solution was incubated for 2 h in the
same conditions, then the inhibition percentages were determined
and they were of the 95% for the solution A and 65% for the
solution B (the activity of the solution C was used as 100% of
enzyme activity).
After the incubation, from the solutions A and B the residual
free inhibitor was removed, the enzyme was washed, and the
activity was determined again. In the case of the compound 4, the
enzyme activity was totally recovered, instead, in the case of
Carbaryl the inhibition percentage became 90%. This result
suggests that the compound 4 does not act as a pseudo-irreversible
inhibitor, because it does not produce the carbamylation of the
enzyme.
We also carried out a mass spectrometry experiment to obtain
another proof of the non-covalent inhibition mechanism of the
compound 4, according to a literature procedure22. Also in this
case, we have prepared three AChE solutions: the first incubated
Table 1. AChE inhibition activity of synthesized carbamates 1–14 and alcohol 15d. The data represent the inhibition percentage at
different inhibitor concentration (see experimental).
R
N O
R
R1
n
Inhibition %
Compound R R1 n at 50mM at 25mM at 12.5mM
1 H CON(CH3)2 1 57 – –
2 H CON(CH3)2 2 41 36 –
3 H CON(CH3)2 3 60 – –
4 H CON(CH3)2 4 85 – –
5 CH3 CON(CH3)2 1 – 8 –
6 CH3 CON(CH3)2 2 – 27 –
7 CH3 CON(CH3)2 3 26 – –
8 CH3 CON(CH3)2 4 69 – –
9 F CON(CH3)2 1 – – 25
10 F CON(CH3)2 2 13 – –
11 F CON(CH3)2 4 12 – –
12 CF3 CON(CH3)2 1 31 – –
13 CF3 CON(CH3)2 2 7 – –
14 CF3 CON(CH3)2 4 31 – –
15d H H 4 32
Scheme 1. Synthetic routes to carbamates
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with compound 4, the second incubated with Carbaryl (positive
control) and the third without inhibitor (negative control). After
incubation and removal of inhibitor excess, the enzyme was
treated with trypsine and the digested peptides were analyzed by
MALDI-TOF-MS. The negative control, AChE without inhibitor,
was analyzed to identify the peaks of trypsin digested AChE;
several peaks appeared in the range of 2000–4000 mass unit.
The comparison of the mass spectra obtained for the three
solutions revealed the presence of a peak at 2659.8 m/z in all
samples, corresponding to the active site peptide (containing
Ser225); in the AChE incubated with Carbaryl also appeared a
peak at 2717.3 m/z, corresponding to the addition of the
CONHCH3 group (the carbamylated active site fragment). On
the contrary, for the compound 4 any carbamylation peak was not
detected.
Overall, the data obtained by MALDI-TOF MS experiments
and those on enzyme inhibition reversibility indicate that the
carbamate 4 does not act through the enzyme carbamoylation.
Rather, it would seem to behave as a slow-binding inhibitor,
which does not bind covalently to the enzyme, but simply requires
a longer time interval to establish the optimal interactions with the
enzyme23.
Molecular docking studies
To support the experimental results obtained by enzymatic
inhibition, we carried out a molecular docking study using
SwissDock freely available on Swiss Institute of Bioinformatics
Website. Three-dimensional crystal structure of TcAChE com-
plexed with donepezil was obtained by RCSB Protein Data Bank
(PDB code: 1EVE). The protein preparation and the molecular
docking results visualization were carried out using the UCSF
Chimera package. The EADock DSS software was able to identify
the native-binding mode of donepezil as the best FF score binding
conformation.
Figure 1 shows the best binding pose of the carbamate 4 in
the active site of TcAChE; it can be observed that the
dibenzylamine moiety is directed inside of the active site and
one of the two aromatic rings approaches the Trp84 (numbering
of the TcAChE). Moreover, the alkyl chain drives the carbamate
group toward the access gorge allowing the H bond interaction
between the carbonyl group of the carbamate and the amide NH
of Phe288.
All studied carbamates 1–14 share this binding orientation but
for those compounds having a shorter alkyl linker the H bond
interaction was lost, or worse alignment of the aromatic portions
was observed.
Conclusion
A set of carbamates, derivatives of N,N-dibenzylamine, were
synthesized and tested as AChE inhibitor. In these compounds,
the aromatic portion is linked to the carbamic one by means of an
alkyl linker of variable length. The obtained inhibition data may
allow us to outline a preliminary set of Structure-Activity
Relationship: (a) the presence of carbamic function greatly
increases the inhibition activity (compare 4 versus 15d); (b) the
optimal alkyl linker contains six methylene units, as indicated by
compounds 4 and 8; (c) the presence of electron-withdrawal
substituents on the aromatic moiety, such as fluorine or
trifluoromethyl, reduces the inhibitory potency, as demonstrated
by compounds 9–14.
As the carbamate inhibitors of AChE usually act through the
carbamylation of the active site serine, we decided to verify if also
the most active compound 4, acts according to this mechanism of
action. In the time-dependent inhibition experiment, we found a
slow onset inhibition activity, which was not related to the serine
carbamylation; in fact, the reversibility study of the inhibition
shows that the AChE readily recovered its activity when the
inhibitor 4 was removed, thus suggesting the establishment of
weak interactions between inhibitor and enzyme. Furthermore,
the MALDI-TOF MS experiment confirmed this data, as no
carbamoylation peaks were found in the trypsin digested AChE
incubated with 4.
The slow onset inhibition showed by the carbamate 4 could be
explained with the high conformational freedom of both its alkyl
linker and N,N-dibenzylamine moieties. This is a typical behavior
observed for slow-binding inhibitors with great steric hindrance or
with great conformational freedom, which requires a delay time in
order that the enzyme and inhibitor adapt their conformations to
each other for the optimal interactions23.
A slow-binding inhibitor presents pharmacological advan-
tages over classical reversible inhibitors, because it shows long
target-residence time, and, as a consequence, a prolonged
efficacy and minimal side effects. Slow-binding inhibitors of
AChE could be considered promising new drugs for the
treatment of neurodegenerative disorders such as Alzheimer
disease and myasthenia.
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